( NYSE:ABBV )

News from AbbVie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 12, 2018, 08:00 ET AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its fourth-quarter 2017 financial results on Friday, Jan. 26, 2018, before the market opens. AbbVie will host a...


Jan 08, 2018, 08:00 ET AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA)...


Dec 20, 2017, 08:00 ET AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from the Phase 3...


Dec 20, 2017, 08:00 ET AbbVie to Present at the 36th Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018. Richard A. Gonzalez,...


Dec 19, 2017, 08:00 ET AbbVie to Present at the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 4, 2018....


Dec 14, 2017, 07:54 ET AbbVie Anuncia Estudo de Fase 3 com Venetoclax, em Combinação com Rituximabe, Atinge Objetivo Primário para Tratamento da Leucemia Linfoide Crônica

- Resultados do estudo MURANO, Fase 3, foram apresentados pela primeira vez, durante o 59o Encontro Anual da Sociedade Americana de...


Dec 12, 2017, 07:30 ET AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint

AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and...


Dec 11, 2017, 10:00 ET IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data on the biologic and cellular mechanisms of IMBRUVICA® (ibrutinib)...


Dec 09, 2017, 12:03 ET IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's...


Dec 05, 2017, 08:00 ET IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the Phase 3 iNNOVATE (PCYC-1127) trial evaluating IMBRUVICA® (ibrutinib)...


Dec 04, 2017, 08:03 ET Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from IMMhance,...


Nov 21, 2017, 09:26 ET Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the American Society of Hematology...


Nov 15, 2017, 07:00 ET AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

AbbVie (NYSE: ABBV) will participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017. Bill Chase,...


Nov 03, 2017, 10:40 ET Hackathon, na Campus Party™ Minas Gerais, Premia Soluções Inovadoras em Saúde em Benefício de Toda Sociedade

A biofarmacêutica global AbbVie patrocina, em parceria com a Campus Party™, o Hackathon "O Cidadão como Protagonista da Saúde". O Hackathon...


Nov 03, 2017, 08:00 ET AbbVie to Present at the Jefferies 2017 London Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, 2017. Bill Chase, executive vice...


Nov 01, 2017, 12:00 ET AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain

AbbVie (NYSE:ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...


Oct 27, 2017, 07:40 ET AbbVie Reports Third-Quarter 2017 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2017. "We are pleased with the significant progress we...


Oct 27, 2017, 07:30 ET AbbVie Increases Quarterly Dividend by 11 Percent

The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 11 percent from $0.64 per share to $0.71 per...


Oct 27, 2017, 07:00 ET AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie (NYSE:ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...


Oct 26, 2017, 08:02 ET Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three...


Oct 24, 2017, 09:00 ET AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that data from 38 abstracts of HUMIRA®...


Oct 24, 2017, 07:00 ET Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease

AbbVie (NYSE:ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, today announced a global strategic...


Oct 18, 2017, 08:30 ET AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting...


Oct 18, 2017, 08:00 ET AbbVie to Present at the 2017 Credit Suisse Health Care Conference

AbbVie (NYSE: ABBV) will participate in the 2017 Credit Suisse Health Care Conference on Wednesday, November 8, 2017. Bill Chase, executive vice...


Oct 11, 2017, 14:57 ET AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017

AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced that it will present new data evaluating...